Xencor Reports Third Quarter 2015 Financial Results and Pipeline Update
, Nov. 3, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biotechnology company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticlePreclinical Data of Xencor's XmAb Bispecific Technology to be Presented at...
MONROVIA, Calif., Nov. 5, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Presents Data on XmAb5871 Program at American College of Rheumatology...
MONROVIA, Calif., Nov. 9, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor's XmAb®5871 Program to be Featured in Poster Presentation at European...
MONROVIA, Calif., May 11, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid...
(Source: Xencor Inc) MONROVIA, Calif., Jan. 29, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid...
MONROVIA, Calif., Jan. 29, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and...
View ArticleAmgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And...
THOUSAND OAKS, Calif. and MONROVIA, Calif., Sept. 16, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that the two companies have entered into a...
View ArticleXencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising...
MONROVIA, Calif., Jan. 29, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleAmgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And...
(Source: Amgen Inc) THOUSAND OAKS, Calif. and MONROVIA, Calif., Sept. 16, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that the two companies have...
View ArticleXencor Reports Fourth Quarter and Full Year 2014 Financial Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., Feb. 19, 2015 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleAmgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And...
(Source: Xencor Inc) THOUSAND OAKS, Calif. and MONROVIA, Calif., Sept. 16, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that the two companies have...
View ArticleAmgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And...
THOUSAND OAKS, Calif. and MONROVIA, Calif., Sept. 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Xencor, Inc. (Xencor) (NASDAQ: XNCR) announced today that the two companies have entered into a...
View ArticleXencor Reports Fourth Quarter and Full Year 2014 Financial Results Conference...
, Feb. 19, 2015 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports Second Quarter 2015 Financial and Operating Results
, Aug. 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports Second Quarter 2015 Financial and Operating Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., Aug. 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb...
(Source: Xencor Inc) MONROVIA, Calif., Dec. 18, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb...
MONROVIA, Calif., Dec. 18, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Provides Update on Two Lead XmAb® Product Candidates and Expansion of...
-- Commenced multi-dose part of Phase 1a trial of XmAb®7195 examining IgE reduction and safety profile - -- Study with subcutaneous formulation of XmAb7195 to begin in 2016 - -- XmAb®13676 named as...
View ArticleXencor Provides Update on Two Lead XmAb® Product Candidates and Expansion of...
(Source: Xencor Inc) MONROVIA, Calif., June 26, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Provides Update on Two Lead XmAb® Product Candidates and Expansion of...
MONROVIA, Calif., June 26, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Reports Fourth Quarter and Full Year 2015 Financial Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Reports Fourth Quarter and Full Year 2015 Financial Results
, March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports First Quarter 2016 Financial Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., May 2, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor Provides Updates on Lead Programs and Reviews Bispecific Oncology...
(Source: Xencor Inc) MONROVIA, Calif., June 28, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Announces Strategic Collaboration for Bispecific Programs, including...
(Source: Xencor Inc) MONROVIA, Calif., June 28, 2016 /PRNewswire/ -- Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that it has entered into a collaboration and license agreement with Novartis to...
View ArticleXencor Reports Second Quarter 2016 Financial Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., Aug. 2, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor Doses First Patient in Lead Immuno-Oncology Bispecific Program...
(Source: Xencor Inc) MONROVIA, Calif., Sept. 12, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Reports Third Quarter 2016 Financial Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., Nov. 2, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor's (XNCR) CEO Bassil Dahiyat on Q4 2016 Results - Earnings Call Transcript
Xencor, Inc. (NASDAQ:XNCR) Q4 2016 Earnings Conference Call February 28, 2017, 04:30 PM ET Executives Hannah Deresiewicz - Stern Investor Relations Bassil Dahiyat - President, Chief Executive Officer...
View ArticleXencor Reports Fourth Quarter and Full Year 2016 Financial Results
MONROVIA, Calif., Feb. 28, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates...
MONROVIA, Calif., March 1, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and...
View ArticleXencor's (XNCR) CEO Bassil Dahiyat on Q1 2017 Results - Earnings Call Transcript
Xencor Inc. (NASDAQ:XNCR) Q1 2017 Earnings Conference Call May 9, 2017, 04:30 PM ET Executives Josh Robinhood - Stern Investor Relations Bassil Dahiyat - President and CEO John Kuch - Vice President,...
View ArticleXencor Reports First Quarter 2017 Financial Results
MONROVIA, Calif., May 9, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor's Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate...
(Source: Xencor Inc) MONROVIA, Calif., Sept. 24, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and...
(Source: Xencor Inc) MONROVIA, Calif., Nov. 11, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Appoints Yujiro S. Hata to Board of Directors
MONROVIA, Calif., July 31, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Reports Complete Data Results on XmAb5871 Program at European League...
MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor's (XNCR) CEO Bassil Dahiyat on Q3 2016 Results - Earnings Call Transcript
Xencor, Inc. (NASDAQ:XNCR) Q3 2016 Earnings Conference Call November 02, 2016 4:30 PM ET Executives Hannah Deresiewicz - Stern Investor Relations Bassil Dahiyat – President, Chief Executive Officer and...
View ArticleXencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and...
MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Appoints Yujiro S. Hata to Board of Directors (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., July 31, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Reports Complete Data Results on XmAb5871 Program at European League...
(Source: Xencor Inc) MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and...
(Source: Xencor Inc) MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor's XmAb®5871 Program to be Featured in Poster Presentation at European...
(Source: Xencor Inc) MONROVIA, Calif., May 11, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
(Source: Xencor Inc) MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor Reports First Quarter 2015 Financial and Operating Results
, May 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports First Quarter 2015 Financial and Operating Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., May 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor's Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate...
MONROVIA, Calif., Sept. 24, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Appoints A. Bruce Montgomery, M.D. to Board of Directors (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., March 19, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View Article